Biothera Pharmaceuticals,

Biothera Pharmaceuticals is a privately held, clinical stage immuno-oncology company developing our proprietary immunotherapy, Imprime PGG, in combination with immune checkpoint inhibitors, or CPIs, for multiple cancer indications. Imprime PGG is a biologic innate immune modulator that activates the immune system and coordinates anti-cancer immune responses that result in increased activation of cancer-specific T cells. Preclinical studies demonstrate that Imprime PGG can enhance the efficacy of anti-cancer immune responses in combination with CPI, tumor-targeting and anti-angiogenic antibodies. The Company has clinical research agreements with Merck, Genentech and AstraZeneca to evaluate Imprime PGG in combination with CPIs in multiple cancer indications, including metastatic triple negative breast cancer, head and neck cancer and colorectal cancer. Imprime PGG has shown strong evidence of tolerability in clinical trials with more than 500 subjects, including over 400 cancer patients. For more information, visit us at www.biothera.com.